FNY Partners Fund’s Editas Medicine EDIT Stock Holding History

FNY Partners Fund’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,000	Closed	-$44K	–	714
2017 Q1	$44K	Buy	+2,000	New	+$41.4K	0.01%	753

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FNY Partners Fund's EDIT Position: Q2 2017 in Review

FNY Partners Fund sold out of Editas Medicine (EDIT) in Q2 2017, closing a stake of 2,000 shares — an estimated $44K sold.

FNY Partners Fund first reported a position in EDIT in Q1 2017 and held it in 1 quarter. The position peaked at $44K in Q1 2017. 110 funds tracked by Wall St. Rank hold EDIT as of Q2 2017.

FNY Partners Fund reported no remaining Editas Medicine position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 2,000 Editas Medicine shares in Q2 2017, an estimated $44K.
FNY Partners Fund first reported a position in Editas Medicine in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's Editas Medicine position peaked at $44K in Q1 2017.
110 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.